Nectero Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$96M
- Investors
-
10
Nectero Therapeutics General Information
Description
Operator of a clinical-stage biotechnology company intended to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company delivers a compound with a stabilizer agent to the site of the aneurysm, which inhibits further breakdown and strengthens the vessel wall, enabling patients to have earlier intervention in a safe manner that prevents or significantly delays the need for major endovascular or surgical repair.
Contact Information
Website
www.necterotherapeutics.comCorporate Office
- 1155 West Rio Salado Parkway
- Suite B-104
- Tempe, AZ 85281
- United States
Corporate Office
- 1155 West Rio Salado Parkway
- Suite B-104
- Tempe, AZ 85281
- United States
Nectero Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 21-Apr-2024 | $96M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series C) | 10-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 01-Apr-2020 | $7M | $8M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | $1M | $1M | Completed | Pre-Clinical Trials |
Nectero Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D-3 | ||||||||
| Series D-2 | ||||||||
| Series D-1 | ||||||||
| Series C | ||||||||
| Series B | 9,487,403 | $0.000100 | 7% | $0.75 | $0.75 | 1x | $0.75 | 8.55% |
| Series A | 819,714 | $0.000100 | $0.1 | $1.27 | $1.27 | 1x | $0.94 | 1% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nectero Therapeutics Comparisons
Industry
Financing
Details
Nectero Therapeutics Competitors (4)
One of Nectero Therapeutics’s 4 competitors is XyloCor Therapeutics, a Venture Capital-Backed company based in King of Prussia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| XyloCor Therapeutics | Venture Capital-Backed | King of Prussia, PA | ||||
| InCarda Therapeutics | Venture Capital-Backed | West Jordan, UT | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA |
Nectero Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nectero Therapeutics Patents
Nectero Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222003-A1 | Regeneration of elastin within degraded connective tissue by delivering a phenolic compound to the connective tissue | Pending | 14-Apr-2025 | ||
| US-20240390403-A1 | Composition and methods for treating an aneurysm | Pending | 25-May-2023 | ||
| US-20250049598-A1 | Systems and methods for treating an aortic tear or dissection | Pending | 24-Nov-2021 | ||
| WO-2023097225-A1 | Systems and methods for treating an aortic tear or dissection | Inactive | 24-Nov-2021 | ||
| EP-3946366-A1 | Methods and devices for treatment of post-surgery laxity of tendons and tendon repair | Inactive | 26-Mar-2019 | A61K31/7024 |
Nectero Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nectero Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| Aphelion Capital | Venture Capital | Minority | ||
| BakerBridge Capital | Venture Capital | Minority | ||
| BioStar Capital | Venture Capital | Minority | ||
| Cadence Healthcare Ventures | Venture Capital | Minority |
Nectero Therapeutics FAQs
-
When was Nectero Therapeutics founded?
Nectero Therapeutics was founded in 2017.
-
Where is Nectero Therapeutics headquartered?
Nectero Therapeutics is headquartered in Tempe, AZ.
-
What is the size of Nectero Therapeutics?
Nectero Therapeutics has 35 total employees.
-
What industry is Nectero Therapeutics in?
Nectero Therapeutics’s primary industry is Therapeutic Devices.
-
Is Nectero Therapeutics a private or public company?
Nectero Therapeutics is a Private company.
-
What is the current valuation of Nectero Therapeutics?
The current valuation of Nectero Therapeutics is .
-
What is Nectero Therapeutics’s current revenue?
The current revenue for Nectero Therapeutics is .
-
How much funding has Nectero Therapeutics raised over time?
Nectero Therapeutics has raised $124M.
-
Who are Nectero Therapeutics’s investors?
Alumni Ventures, Aphelion Capital, BakerBridge Capital, BioStar Capital, and Cadence Healthcare Ventures are 5 of 10 investors who have invested in Nectero Therapeutics.
-
Who are Nectero Therapeutics’s competitors?
XyloCor Therapeutics, InCarda Therapeutics, Cytokinetics, and Verve Therapeutics are competitors of Nectero Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
